For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Attruby represents a significant breakthrough . These groundbreaking therapies preserve the transthyretin protein, halting its harmful build-up and alleviating the severity of the illness. Patients are now seeing positive